PBA
MBX

Paradigm Biocapital Advisors’s MBX Biosciences MBX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138M Buy
+2,508,015
New +$87.6M 2.59% 14

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Paradigm Biocapital Advisors's MBX Position: Q2 2026 in Review

Paradigm Biocapital Advisors opened a new position in MBX Biosciences (MBX) in Q2 2026: 2,508,015 shares worth $138M. The stake represents 2.59% of the portfolio and ranks #14 among its holdings.

138 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Paradigm Biocapital Advisors held 2,508,015 shares of MBX Biosciences worth $138M as of Q2 2026.
  • MBX Biosciences was a new Paradigm Biocapital Advisors position in Q2 2026.
  • MBX Biosciences made up 2.59% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #14 holding.
  • 138 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.